Summary of Federal Cooperative Agreement Award

Comagine Health received a $530,298 cooperative agreement awarded August 30, 2025, by the Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion under the Organized Approaches to Increase Colorectal Cancer Screening program (CFDA 93.800). In partnership with the Idaho Community Health Center Association, Comagine Health will implement a comprehensive, evidence-based initiative to increase colorectal cancer screening rates among rural Idahoans aged 45-75 receiving care at Federally Qualified Health Centers. The project targets five FQHCs collectively serving 121,519 patients with screening rates below the national average and will operate through a five-year performance period concluding August 29, 2030.

The cooperative agreement funds a phased, cohort-based service delivery model employing two successive cohorts of FQHCs over 2.5 years each. Core services include collaborative outreach and readiness assessments to identify and recruit participating FQHCs while addressing structural barriers such as transportation and financial assistance; facilitation of quarterly learning collaborative sessions and monthly technical assistance using the IHI Breakthrough Series Model to implement evidence-based interventions including patient reminders, provider reminders, provider assessment and feedback, and patient navigation services; and comprehensive monitoring and evaluation activities utilizing the Azara Population Health System to track screening and follow-up data with quarterly performance reporting. The first cohort will transition to a mentorship role supporting the second cohort, ensuring sustainability of quality improvement practices and system-level improvements aimed at reducing screening disparities in rural Idaho.